Acriptega Tablet

Acriptega Tablet contains Dolutegravir, Lamivudine and Tenofovir Disoproxil Fumarate is an antiretroviral medication used in the management of HIV-1 infection.

Brand Name: Acriptega

Composition: Dolutegravir, Lamivudine, Tenofovir Disoproxil Fumarate

Mechanism of Action:

The reverse transcriptase enzyme is inhibited by tenofovir, which stops viral RNA from being converted to DNA and stops the virus from multiplying inside the host cells. By lowering the blood's viral load, this dual action strengthens the immune system and lowers the risk of consequences from HIV.

Uses:

HIV Infection

Dosage and Administration:

One tablet taken once a day, with or without food, is the usual dosage.

Side Effects:

• Fatigue
• Headache
• Nausea
• Vomiting
• Fever
• Cough
• Insomnia
• Liver Function Abnormalities
• Allergic Reactions

Safety Advise:

Kidney  

Monitor kidney function regularly, as Acriptega can cause nephrotoxicity. Kindly speak with your healthcare provider.

Liver  

Monitor liver function regularly, as Acriptega can cause liver impairement. Kindly speak with your healthcare provider.

Pregnancy  

Acriptega should be used during pregnancy only if clearly needed, Kindly speak with your healthcare provider.

Breast Feeding  

Using Acriptega while nursing is most likely dangerous. Kindly speak with your healthcare provider.

Alcohol  

Acriptega should not be taken with alcohol. Kindly speak with your healthcare provider.

Storage:

Store Acriptega Tablet at a temperature between 15°C and 30°C (59°F to 86°F). Keep the tablets in the original packaging to protect them from light and moisture. Keep out of reach of children.

How to use this Medication?

Drink a glass of water along with this prescription. Take it daily at the same time as specified on the prescription label. Consume it with food. Take each dose exactly as directed on the prescription label for the best potential outcome from your therapy. Don't miss any dosages. The virus may become resistant to this and other medications if doses are skipped. Unless instructed otherwise by your care team, continue taking this therapy.

 

Discuss the usage of this drug in children with your care team. For certain illnesses, it can be administered to youngsters as young as 12, although there are safety precautions to take.

References:

1.     Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. The Lancet. 2019 Jan 12;393(10167):143-55.

2.      Scott LJ. Dolutegravir/lamivudine single-tablet regimen: a review in HIV-1 infection. Drugs. 2020 Jan;80(1):61-72.

3.   Venter WD, Sokhela S, Simmons B, Moorhouse M, Fairlie L, Mashabane N, Serenata C, Akpomiemie G, Masenya M, Qavi A, Chandiwana N. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial. The lancet HIV. 2020 Oct 1;7(10):e666-76.

Reference:

1.     Tenofovir disoproxil. Limassol, Cyprus: Remedica Ltd.; 2018. [Accessed 24 Jan. 2019] (online) 

2.     Dolutegravir. Research Triangle Park, North Carolina: GlaxoSmithKline; 2013. [Acccessed 24 Jan. 2019] (online)

Disclaimer:

The main goal of Apothecare Wellness is to make sure that the information it provides to customers is correct, reliable, and reviewed by specialists. This website's contents and information are strictly for informational purposes. They are not meant to be used in place of expert medical advice, diagnosis, or care. Please consult your physician for guidance and ask any questions you may have about any condition or medication. If you read anything on Apothecare Wellness, do not discount or delay obtaining competent medical advice. Our goal is to enhance the doctor-patient relationship, not to take its place.

Marketer details

Name: Mylan Pharmaceuticals Pvt Ltd

Address: Plot No A-1/2, MIDC Industrial Area, Taloja MIDC-410208.

Country of origin: India